ACTG A5142

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 A5142是一项第三阶段的随机三臂开放标签研究，比较了以下方案对艾滋病毒感染的初始治疗的有效性： 基于非核苷逆转录酶抑制物(NNRTI)的方案(efavirenz[EFV]+司他夫定缓释剂[d4T XR](或齐多夫定[ZDV]或富马酸替诺福韦[TDF])+拉米夫定[3TC]) 利托那韦(RTV)增强型蛋白酶抑制剂(PI)方案(Lopinavir/ritonavir[LPV/RTV]+d4T XR[或ZDV或TDF]+3TC) 核苷逆转录酶抑制剂(NRTI)-Sparing方案(EFV加LPV/RTV)

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A5142 is a phase III, randomized, three-arm, open-label study comparing the effectiveness of the following regimens for the initial treatment of HIV infection: Nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimen (efavirenz [EFV] plus stavudine extended release [d4T XR] (or zidovudine [ZDV] or tenofovir disoproxil fumarate [TDF]) plus lamivudine [3TC]) Ritonavir (RTV)-enhanced protease inhibitor (PI)-based regimen (lopinavir/ritonavir [LPV/RTV] plus d4T XR [or ZDV or TDF] plus 3TC) Nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimen (EFV plus LPV/RTV)